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The past decade witnessed a revolution in molecular targeted
therapy against cancer. Development of drugs for speciﬁc
biological pathways with increased speciﬁcity and reduced
toxicityhasvalidatedthelong-heldbeliefinthecancerresearch
community that a precise molecular understanding of cancer
can result in cancer therapy. One of the most successful recent
examples of cancer-speciﬁc drugsis development of Herceptin,
a monoclonal antibody against the HER2 receptor for breast
cancer therapy. HER2 is an important target in cancer because
its overexpression increases tumor cell proliferation, vessel
formation and invasiveness and predicts poor prognosis.
Disabling the Her2/neu receptor kinase complex with ecto-
domain binding monoclonal antibodies (e.g., Herceptin) leads
to a reversal of the malignant phenotype of tumor cells and
has therapeutic and preventative applications for human
malignancy.DespitetheimportantroleofHER2overexpression
in tumor progression for a variety of human cancers, the
mechanismby whichtheoverexpressiondysregulatesdifferent
signaling networks in cells is poorly understood.
In a study currently published in Molecular Systems Biology,
Wolf-Yadlin et al (2006) make an important contribution to
elucidation of this mechanism by studying the effects of HER2
overexpression on EGF- and HRG-mediated signaling of erbB
receptors. To that end, they used quantitative mass spectro-
metry to study the phosphorylation kinetics of speciﬁc
phosphorylation sites in a variety of proteins involved in the
erbB receptor signaling network and compared the results
obtainedinhumanmammaryepithelialcellswithlowandhigh
expression levels of HER2. In addition to establishing links
between erbB receptor dimerization and activation of speciﬁc
phosphorylationsitesthatregulateproliferationandmigration,
the study enabled identiﬁcation of novel proteins and
phosphorylation sites involved in the erbB signaling pathway.
To quantify the effects of HER2 overexpression in a human
mammary epithelial cell (HMEC) line 184A1, the authors
compared the parental cell line containing approximately
20000 HER2 receptors per cell with a stable retrovirally
transduced clone that expresses approximately 600000 HER2
receptorspercellandacomparablenumberofEGFRandHER3.
Both parental and HER2-overexpressing cells were stimulated
with either EGFor HRG and the temporal dynamics of tyrosine
phosphorylation was studied by mass spectrometry after 0, 5,
10 and 30min of ligand stimulation. The study identiﬁed 332
phosphorylated peptides from 175 proteins. A total of 20
phosphorylation sites were identiﬁed on EGFR, HER2 and
HER3 including three novel sites (Y1114 on EGFR and Y1005
and Y1127 on HER2) that have not been previously described
in literature. In addition, phosphorylation sites on 15 different
proteins in the EGFR canonical signaling pathway and on 16
proteins in the cell adhesion/migration pathway have been
quantitatively analyzed. The study makes an original con-
tribution to the ﬁeld by identifying 122 novel phosphorylation
sites that have not been previously described in literature.
Using computational methods, including self-organizing map
clustering and partial least-squares regression analysis, it also
identiﬁes speciﬁc combinations of phosphorylation sites that
correlate with cell proliferation and migration and that can
potentially represent targets for therapeutic intervention.
The study showed that overexpression of HER2 promotes
increased cell migration, but does not signiﬁcantly effect cell
proliferation. Notable differences have been observed in cell
migration between EGF- and HRG-stimulated cells that over-
express HER2. EGF stimulation of HER2-overexpressing cells
promoted migration by phosphorylation of proteins that
belong to different pathways, including PI3K, MAPK, catenins
and FAK. In contrast, HRG stimulation led to activation of a
morespeciﬁcsubsetofproteins,inparticularFAK,Src,paxillin
and p130Cas. Cell proliferation was not affected by HER2
overexpression and was primarily driven by EGF stimulation.
Unfortunately, owing to sensitivity limitations, only 68 out
of 322 phosphorylation sites could be analyzed kinetically
using all stimulation conditions and therefore the study does
not provide a comprehensive analysis of the multitude of
effects produced by HER2 overexpression. It does, however,
mark an important breakthrough in characterization of the
erbB receptor signaling network in tumors. Advances in the
understanding of how tumor cells differ from normal tissue
have made possible the development of a newclass of targeted
cancer therapies that interrupt processes important to tumor
survival and progression.
However, in spite of recent advances in molecular biology
leading to the introduction of clinically active novel agents,
therapy of the most common epithelial tumors remains
limited. The resistance to monotherapy can be at least partly
explained by the diversity of molecular abnormalities in the
tumors, suggesting that the efﬁcacy of cancer therapy could be
improved by using combinations of anticancer agents that
target complementary signaling pathways. Concerted inhibi-
tion of multiple pathways required for tumor growth and
progression could have a synergistic effect, resulting in a more
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Article number: 55effective inhibition of tumor growth. Recently, a number of
studies described important links of the EGFR signaling
pathwaywithproteinsthatbelongtootherpathwaysincluding
survivin (Wang and Greene, 2005), TRAIL (Dubska et al,
2005), VEGFR (Ciardiello et al, 2006), GPCRs (Ohtsu et al,
2006), among others. Two papers used proteomics and
microarray approaches to study protein interactions with
tyrosine phosphorylation sites oferbB receptors(Schulze et al,
2005; Jones et al, 2006; Uetz and Stagljar, 2006). The study
by Wolf-Yadlin et al opens the way to a more thorough
characterization of the EGFR signaling network in tumor cells
by identifying proteins and phosphorylation sites activated at
overexpressed levels of HER2, a condition known to be vital
for the progression of numerous tumors. The identiﬁed sites
can now be further characterized and the nature of their
relationship with the EGFR pathway as well as signiﬁcance as
therapeutic targets can be studied in more detail.
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